QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ziegler, C. C. Articles by McEntee, M. F. Search for Related Content PubMed PubMed Citation Articles by Ziegler, C. C. Articles by McEntee, M. F.

---

Biochemical and Molecular Actions of Nutrients

Dietary Resveratrol Does Not Affect Intestinal Tumorigenesis in Apc^Min/+ Mice¹

Department of Nutrition and ^* Department of Pathology, University of Tennessee, Knoxville, TN

²To whom correspondence should be addressed. E-mail: mmcentee{at}utk.edu.

To determine its effect on intestinal tumorigenesis and the protumorigenic COX pathway in Apc^Min/+ mice, resveratrol was administered as a powdered admixture in the diet at 0, 4, 20, or 90 mg/kg body weight for 7 wk. In two separate experiments, resveratrol did not affect intestinal tumor load. It was stable in the diet under experimental conditions, circulated in the plasma as the glucuronide-conjugated form and reached the tumors as evidenced by significant decreases in PGE₂ levels. However, immunohistochemical staining of intestinal tumors revealed no changes in COX-2 expression. This study demonstrates that resveratrol consumed ad libitum in the diet, does not modify tumorigenesis in Apc^Min/+ mice.

KEY WORDS: • cancer • resveratrol • Apc • phytochemical • COX-2

This article has been cited by other articles:

				A K Lawrance, L Deng, and R Rozen Methylenetetrahydrofolate reductase deficiency and low dietary folate reduce tumorigenesis in Apcmin/+ mice Gut, June 1, 2009; 58(6): 805 - 811. [Abstract] [Full Text] [PDF]

				A. Bishayee Cancer Prevention and Treatment with Resveratrol: From Rodent Studies to Clinical Trials Cancer Prevention Research, May 1, 2009; 2(5): 409 - 418. [Abstract] [Full Text] [PDF]

				D. J. Boocock, G. E.S. Faust, K. R. Patel, A. M. Schinas, V. A. Brown, M. P. Ducharme, T. D. Booth, J. A. Crowell, M. Perloff, A. J. Gescher, et al. Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1246 - 1252. [Abstract] [Full Text] [PDF]

				A. A. Baran, K. A. Silverman, J. Zeskand, R. Koratkar, A. Palmer, K. McCullen, W. J. Curran Jr, T. B. Edmonston, L. D. Siracusa, and A. M. Buchberg The modifier of Min 2 (Mom2) locus: Embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression Genome Res., May 1, 2007; 17(5): 566 - 576. [Abstract] [Full Text] [PDF]

				R. M. Niles, C. P. Cook, G. G. Meadows, Y.-M. Fu, J. L. McLaughlin, and G. O. Rankin Resveratrol Is Rapidly Metabolized in Athymic (Nu/Nu) Mice and Does Not Inhibit Human Melanoma Xenograft Tumor Growth J. Nutr., October 1, 2006; 136(10): 2542 - 2546. [Abstract] [Full Text] [PDF]

				A. E. Moran, A. M. Carothers, M. J. Weyant, M. Redston, and M. M. Bertagnolli Carnosol Inhibits {beta}-Catenin Tyrosine Phosphorylation and Prevents Adenoma Formation in the C57BL/6J/Min/+ (Min/+) Mouse Cancer Res., February 1, 2005; 65(3): 1097 - 1104. [Abstract] [Full Text] [PDF]